NAMS vs MBX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
NAMS · NewAmsterdam Pharma$18.41 ▼ 5.64%
MBX · MBX Biosciences$49.55 ▼ 7.23%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- NAMS -53.2%
- MBX +58.6%
Head to head
| Metric | NAMS | MBX |
|---|---|---|
| Price | $18.41 | $49.55 |
| Change today | ▼ 5.64% | ▼ 7.23% |
| Market cap | $2.21B | $2.46B |
| Return, 3 months | -31.4% | -25.4% |
| Return, year to date | -47.5% | +57.1% |
| Return, 1 year | -51.9% | +83.0% |
| P/E (TTM) | – | – |
| P/B | 3.5 | 5.2 |
| P/E percentile vs own 5y | 27th | 26th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +5,406.9% | – |
| Net profit growth (YoY) | +75.9% | -188.7% |
| Gross margin | – | – |
| Operating margin | -900.1% | – |
| Net margin | -789.9% | – |
| Return on equity | -30.2% | -33.7% |
| Analyst target vs. price | +195.7% | +98.4% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 38 | 41 |
| 30-day volatility | 64.1% | 66.3% |
| Max drawdown, 1 year | -55.6% | -37.6% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MBX is the largest of the group by market value.
- MBX has returned the most over the past year.
- NAMS has been the calmest stock over the last 30 days.